FERRIC CITRATE MONOHYDRATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H5O7.Fe.H2O
Molecular Weight	262.96
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.[Fe+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=AJVRSHNXSHMMCH-UHFFFAOYSA-K

InChI=1S/C6H8O7.Fe.H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;1H2/q;+3;/p-3

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Fe
Molecular Weight	55.845
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C6H6O7
Molecular Weight	190.1076
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.mfc.co.jp/english/eng/product/sanferol/pdf/fls_gras_notice.pdfhttps://mistralhowto.wordpress.com/2012/03/12/what-is-pigment-yellow-42-and-what-is-it-used-for/ | http://sensientfoodcolors.com/en-us/confection/iron-oxides-approved-by-the-fda/ | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=73.2250 | https://www.drugs.com/inactive/ferric-oxide-yellow-381.htmlhttps://books.google.ru/books?id=vxtxWneRBN4C&pg=PA1103&#v=onepage&q&f=falsehttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000PharmR.pdfhttp://www.edta-chelate.com/ferric-ammonium-edta-liquid--1640836.htmlhttps://books.google.ru/books?id=3hLmyma2-MsC&pg=PA241&lpg=PA241&dq=FERRIC+AMMONIUM+CHLORIDE retrieved from A Consumer's Dictionary of Cosmetic Ingredients, 7th Edition: Complete Information About the Harmful and Desirable Ingredients Found in Cosmetics and Cosmeceuticals By Ruth Winterhttps://www.ncbi.nlm.nih.gov/pubmed/27995746 | http://onlinelibrary.wiley.com/doi/10.1002/047084289X.rn01568/abstract?userIsAuthenticated=false&deniedAccessCustomisedMessage=https://cameochemicals.noaa.gov/chemical/3468 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/27684194 | https://www.ncbi.nlm.nih.gov/pubmed/17511797 | https://www.ncbi.nlm.nih.gov/pubmed/1427505
Curator's Comment: description was created based on several sources, including https://www.gpo.gov/fdsys/pkg/CFR-1996-title21-vol3/pdf/CFR-1996-title21-vol3-sec182-5375.pdf

Ferric chloride is a compound used as a food additive, a haemostatic or treatment for hypochromic anaemia. Ferric chloride induced vascular injury is a widely used model of occlusive thrombosis that reports platelet activation and aggregation in the context of an aseptic closed vascular system. Iron i.v. ferric chloride (960 mg) has being shown to be effective in correcting anaemia in HD patients with iron deficiency.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
transformed cell apoptotic process 108 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21121365	Activator 1430
Phosphate 44 Target ID: CHEMBL2364184 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000PharmR.pdf	Chelating Agent 142

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Unknown 2578
Parenteral Nutrition 50 Sources: https://www.hpra.ie/img/uploaded/swedocuments/2124555.PA0566_015_002.9e9eecde-fb07-4612-8f14-39d5233b7ace.000001Product%20Leaflet%20Approved.150327.pdf https://www.ncbi.nlm.nih.gov/pubmed/20377770	Primary	Approved 8429	Additrace N Approved Use A source of electrolytes and trace elements as an integral part of a complete intravenous nutritional regimen, for adults and children over 40 kg.
Iron deficiency 80 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17511797	Preventing	Approved 8429	Parmirin Approved Use Preventive treatment of iron deficiency
Dental diseases 45 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13224146 https://www.ncbi.nlm.nih.gov/pubmed/286710	Primary	Basic research	Unknown Approved Use Unknown
Iron deficiency anemia 56 Sources: http://www.mfc.co.jp/english/eng/product/sanferol/page/3_11.html	Primary	Approved 8429	SANFEROL Approved Use It has also been reported that SFC preparation improved iron deficiency in a pregnant woman with iron deficiency anemia whose hemoglobin level had not increased after administration of other iron preparations such as ferrous fumarate. A dairy supplemental dose of SFC improved iron deficiency in young women with iron deficiency.
Unknown 2578
Pain 614 Sources: https://www.drugs.com/inactive/ferric-oxide-yellow-381.html https://www.drugs.com/imprints/op-40-16159.html	Inactive ingredient	Approved 8429	Oxycontin Approved Use OxyContin is used in the treatment of chronic pain; pain and belongs to the drug class narcotic analgesics. Launch Date 1998
Unknown 2578
Radioactive cesium and/or radioactive or non-radioactive thallium internal contamination 44 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021626lbl.pdf	Curative	Approved 8429	RADIOGARDASE Approved Use Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. Launch Date 2003
Chronic kidney disease 56 Sources: https://www.drugs.com/pro/ferric-citrate-tablets.html	Palliative	Approved 8429	AURYXIA Approved Use Ferric Citrate is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Launch Date 2014

PubMed

Title	Date	PubMed
The absorption of iron as supplements in infant cereal and infant formulas.	1975 May	165454
Contact dermatitis to yellow iron oxide.	1985 Aug	4064645
New phosphate binding agents: ferric compounds.	1999 Jun	10361865
Non-invasive and non-destructive micro-XRF and micro-Raman analysis of a decorative wallpaper from the beginning of the 19th century.	2007 Feb	16838156
Interaction of omapatrilat with FD&C Blue No. 2 lake during dissolution of modified release tablets.	2007 Jul 18	17398043
Fabrication of FeF3 Nanoflowers on CNT branches and their application to high power lithium rechargeable batteries.	2010 Dec 7	20954196
FeF(3) catalyzed cascade C-C and C-N bond formation: synthesis of differentially substituted triheterocyclic benzothiazole functionalities under solvent-free condition.	2014 May	24504377
Mechanisms and origins of the switchable regioselectivity of FeBr3-catalyzed [1,2]-aryl and [1,2]-alkyl shifts of α-aryl aldehydes.	2016 Feb 28	26822257
Halide Influence on Molecular and Supramolecular Arrangements of Iron Complexes with a 3,5-Bis(2-Pyridyl)-1,2,4,6-Thiatriazine Ligand.	2016 Jun 6	27152549
Iron-Catalyzed Regioselective Transfer Hydrogenative Couplings of Unactivated Aldehydes with Simple Alkenes.	2016 May 17	27072872
Ferric Chloride-induced Murine Thrombosis Models.	2016 Sep 5	27684194
Effect of iron and carbon monoxide on fibrinogenase-like degradation of plasmatic coagulation by venoms of four Crotalus species.	2017 Jan	26845427

Patents

Sample Use Guides

In Vivo Use Guide

Ferric sodium citrate is an additive used in various foods such as baby milk powder, school and hospital food, beverages, cereals and supplements. It is administered orally.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 21:30:50 GMT 2023` Edited by `admin` on `Fri Dec 15 21:30:50 GMT 2023`
Record UNII	334S8T6LKE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FERRIC CITRATE MONOHYDRATE

Common Name

English

1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, IRON(3+) SALT, HYDRATE (1:1:1)

Common Name

English

IRON(III) CITRATE TRIBASIC MONOHYDRATE

Common Name

English

Code System Code Type Description

CHEBI

144434